PMC3806693_01
First patient. a Baseline; b after 4 weeks of ustekinumab treatment; c after 12 weeks of ustekinumab treatment.
cde-0005-0254-g01.jpg
PMC3806693_01_cde-0005-0254-g01.jpg
F1
After 4 weeks of treatment, the patient showed an excellent and rapid improvement (fig. 1b) with a reduction of the PASI score to 10 and the absence of fever and itching. After 12 weeks of therapy, the patient showed complete resolution of the clinical picture with the presence of only mild scaling and a PASI score of 3 (fig. 1c).
PMC3806693_02
Second patient. a Baseline; b after 2 weeks of ustekinumab treatment; c after 12 weeks of ustekinumab treatment.
cde-0005-0254-g02.jpg
PMC3806693_02_cde-0005-0254-g02.jpg
F2
Treatment with intravenous methylprednisolone and ranitidine hydrochloride temporarily improved her clinical condition, but an erythrodermic relapse (PASI score: 40) was observed despite the patient undergoing treatment with small doses of oral corticosteroids (fig. 2a). Therapy with ustekinumab at the dosage of 45 mg s.c. was started as monotherapy, and after only 2 weeks (fig. 2b), the patient experienced an improvement of her clinical features with a visible reduction of erythema and scaling, achieving an improvement of her PASI score from baseline exceeding 75% (PASI score: 8.4). A second dose was administered 4 weeks later, and after 3 months, the patient showed a PASI score of 0 with a satisfactory control of articular symptoms, using ketoprofen as needed (fig. 2c).